Close Menu

Quanterix

For the three months ended Sept. 30, the Billerica, Massachusetts-based company posted Q3 revenues of $31.4 million, up from $14.9 million in Q3 2019.

The company's recent license agreement with Abbott is part of its plan to move its Simoa technology into the clinic via partners in LDT and IVD development.

The awards will support clinical validation, manufacturing, and scale up for SARS-CoV-2 viral antigen and molecular detection.

Under the non-exclusive license, Quanterix will receive an initial license fee, milestone fees and launch milestones, and royalties.

While the test is unlikely to be used as a diagnostic for the virus, it could be useful for identifying patients at high risk of developing severe disease.

News items for the in vitro diagnostics industry for the week of August 10, 2020.

The company said that it has priced a public offering of 2,651,108 shares of its common stock at $32 per share.

The company posted Q2 revenues of $13.1 million, down from $13.5 million in Q2 2019 but above the consensus Wall Street estimate of $11.8 million.

The researchers found that levels of the marker, which has also been studied in diseases like MS and Alzheimer's, correlated with severity of traumatic brain injury.

The company posted Q1 revenues of $15.7 million, up from $12.3 million in Q1 2019 and above the consensus Wall Street estimate of $13.3 million.

Pages